Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Protoc Pharmacol. 2013 Mar;Chapter 2:Unit2.9. doi: 10.1002/0471141755.ph0209s60.

The human kinome and kinase inhibition.

Author information

1
Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

Abstract

Protein and lipid kinases play key regulatory roles in a number of biological processes. Unsurprisingly, activating mutations in kinases have been linked to a number of disorders and diseases, most notably cancers. Thus, kinases have emerged as promising clinical targets. There are more than 500 human protein kinases and about 20 lipid kinases. Most protein kinases share a highly conserved domain, the eukaryotic protein kinase (ePK) domain, which contains the ATP and substrate-binding sites. Many inhibitors in clinical use bind to the highly conserved ATP binding site. For this reason, many kinase inhibitors are not exclusively selective for their intended targets. Furthermore, despite the current interest in kinase inhibitors, very few kinases implicated in disease have validated inhibitors. This unit describes the human kinome, ePK structure, and types of kinase inhibitors, focusing on methods to identify potent and selective kinase inhibitors.

PMID:
23456613
PMCID:
PMC4128285
DOI:
10.1002/0471141755.ph0209s60
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center